3-[6-[3-(Oxan-2-yloxyamino)-3-oxoprop-1-enyl]pyridin-2-yl]prop-2-enoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-[6-[3-(Oxan-2-yloxyamino)-3-oxoprop-1-enyl]pyridin-2-yl]prop-2-enoic acid
• 英文别名: 3-[6-[3-(oxan-2-yloxyamino)-3-oxoprop-1-enyl]pyridin-2-yl]prop-2-enoic acid
• 化学式: C₁₆H₁₈N₂O₅
• 分子量: 318.32
• InChiKey: AWWBCJWUWYUSMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  97.8
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Heterocyclic derivatives as HDAC inhibitors
  申请人：DAC S.r.l.

  公开号：EP2133334A1

  公开（公告）日：2009-12-16

  This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; R1 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1 C6 haloalkoxy; R2, R3 are, independently, hydrogen; C1-C6 alkyl; aryl; or taken together with the carbon atoms to which they are bound form a bridged bicyclic ring or a fused heterocycle; X is CH or nitrogen; Y is a bond, oxygen, (CH2)mCR4R5(CH2)n, or (CH2)oNR6(CH2)p; m, n, o, p, R4, R5 and R6 are as further defined in the specification; and pharmaceutical acceptable salts thereof.

  这项发明涉及新的组蛋白去乙酰化酶抑制剂，其通式如下（I）：其中：虚线是可选的额外键；R1是氢、卤素、C1-C6烷基、C1-C6烷氧基、C1-C6卤烷基或C1-C6卤烷氧基；R2、R3分别是氢、C1-C6烷基、芳基；或者与它们相结合的碳原子形成桥接的双环或融合的杂环；X是CH或氮；Y是键、氧、（CH2）mCR4R5（ ）n、或（ ）oNR6（ ）p；m、n、o、p、R4、R5和R6如规范中进一步定义；以及其药用可接受盐。
• HETEROCYCLIC DERIVATIVES AS HDAC INHIBITORS
  申请人：Thaler Florian

  公开号：US20110105474A1

  公开（公告）日：2011-05-05

  This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; R 1 is hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl or C 1 C 6 haloalkoxy; R 2 , R 3 are, independently, hydrogen; C 1 -C 6 alkyl; aryl; or taken together with the carbon atoms to which they are bound form a bridged bicyclic ring or a fused heterocycle; X is CH or nitrogen; Y is a bond, oxygen, (CH 2 ) m CR 4 R 5 (CH 2 ) n , or (CH 2 ) o NR 6 (CH 2 ) p ; m, n, o, p, R 4 , R 5 and R 6 are as further defined in the specification; and pharmaceutical acceptable salts thereof.

  这项发明涉及到新的组蛋白去乙酰化酶抑制剂，其一般式为（I），其中：虚线是可选的附加键；R1是氢、卤素、C1-C6烷基、C1-C6烷氧基、C1-C6卤代烷基或C1-C6卤代烷氧基；R2、R3独立地是氢、C1-C6烷基、芳基或者与它们所结合的碳原子形成桥接的双环环或融合的杂环；X是CH或氮；Y是键、氧、（CH2）mCR4R5（ ）n或（ ）oNR6（ ）p；m、n、o、p、R4、R5和R6如规范中所定义；以及其药物可接受的盐。
• [EN] HETEROCYCLIC DERIVATIVES AS HDAC INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES COMME INHIBITEURS DES HDAC
  申请人：DAC SRL

  公开号：WO2009150129A1

  公开（公告）日：2009-12-17

  This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; R1 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1-C6 haloalkoxy; R2, R3 are, independently, hydrogen; C1-C6 alkyl; aryl; or taken together with the carbon atoms to which they are bound form a bridged bicyclic ring or a fused heterocycle; X is CH or nitrogen; Y is a bond, oxygen, (CH2)mCR4R5(CH2)n, or (CH2)oNR6(CH2)p; m, n, o, p, R4, R5 and R6 are as further defined in the specification; and pharmaceutical acceptable salts thereof.